1. Introduction {#sec1}
===============

Coronary artery disease (CAD) has reached epidemic proportions in the Asian Indian population. Asian Indians have a propensity for premature, diffuse, and severe CAD.[@bib1], [@bib2] Genome-wide association studies starting from 2007[@bib3], [@bib4], [@bib5], [@bib6], [@bib7] identified the 9p21.3 chromosomal region as being strongly associated with CAD and myocardial infarction (MI). This region has also been associated with stroke,[@bib8], [@bib9] aortic,[@bib10] abdominal,[@bib11] intracranial aneurysms,[@bib10] and several types of cancers.[@bib12], [@bib13], [@bib14]

The chromosomal region 9p21.3 has been strongly associated with CAD in Caucasian, Italian,[@bib15] US Hispanic,[@bib16] Chinese,[@bib17] Japanese,[@bib18] Korean,[@bib19] Asian Indian,[@bib20] and Pakistani[@bib21] populations. This region is sparse in genes and also called 'gene desert'. The nearest genes, about 100 kb upstream of the core CAD region, are two tumor suppressor genes called *CDKN2A* and *CDKN2B* that constitute the *INK4/ARF* locus. This locus encodes cyclin-dependent kinase inhibitors (p16^INK4A^ and p14^ARF^ from *CDKN2A* and p15^INK4B^ from *CDKN2B*) that cause arrest of cell cycle in the G1 phase.[@bib22], [@bib23] Further away is another gene *MTAP* that encodes methylthioadenosine phosphorylase, that is involved in the polyamine pathway (salvage of adenine and methionine).[@bib24] Most of the single-nucleotide polymorphisms (SNPs) associated with CAD are present in a 58 Kb region called the 'core CAD' region. The core CAD region overlaps *CDKN2B* and also contains a long noncoding RNA of about 126 kb named *ANRIL* for antisense noncoding RNA in the INK4 locus, hence also called *CDKN2B-AS*. *ANRIL* is known to have several linear[@bib25], [@bib26], [@bib27] and circular isoforms.[@bib27]

The association of the 9p21.3 risk locus with CAD is believed to be mediated via *ANRIL*.[@bib28], [@bib29], [@bib30] Genetic variants associated with CAD are located within intronic and 3′ flanking sequences of *ANRIL*. *ANRIL* is known to be involved in the regulation of *CDKN2A*, *CDKN2B*,[@bib25], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34] possibly *MTAP*, and several other genes involved in the cardiovascular pathway.[@bib35] Repression of *CDKN2A* and *CDKN2B* is known to cause smooth muscle cell proliferation that occurs at the coronary artery wall during the initial stages of atherosclerosis.[@bib36]

To understand the association of the 9p21 risk locus with CAD and premature CAD, we aimed to study 30 SNPs in this region, their association with demographic, clinical characteristics, and interferon alpha 21 (IFNA21) levels in an Asian Indian population.

2. Materials and methods {#sec2}
========================

The study was conducted in the south Indian state of Telangana, in the twin cities of Hyderabad and Secunderabad. The study population consisted of 661 individuals including 443 controls and 218 angiographically documented CAD cases (recruited from June 2015 to June 2017). The controls were recruited from various parts of the twin cities of Hyderabad and Secunderabad. We have followed the guidelines of the 1975 Declaration of Helsinki in the recruitment of study subjects, sample, and data collection. The CAD cases were recruited from Krishna Institute of Medical Sciences (KIMS), Secunderabad, after the approval of the Ethics Committee of KIMS Foundation and Research Centre. Written informed consent was taken from all subjects prior to sample and data collection.

2.1. Selection criteria of study subjects {#sec2.1}
-----------------------------------------

Inclusion criteria for controls include healthy individuals from the age of 40 to 85 years.

Exclusion criteria for controls include individuals with CAD, stroke, and peripheral artery disease.

Inclusion criteria for cases include angiographically documented CAD cases who showed at presentation unstable angina/ST segment elevation myocardial Infarction (STEMI)/Non-ST segment Elevation Myocardial Infarction (NSTEMI), aged 30--85 years.

Exclusion criteria for cases include individuals with liver, kidney, and gastrointestinal disorders and individuals with infectious diseases such as hepatitis, HIV, TB, and so on.

2.2. Methodology {#sec2.2}
----------------

The CAD cases were recruited in consultation with the hospital cardiologist. Peripheral blood sample of 5 ml was taken from each subject and equally dispensed in a vacutainer tube coated with EDTA for plasma and vacutainer tube with clot accelerator for serum separation. DNA extraction from plasma was performed using the kit manufactured by Epicentre (an Illumina company). The DNA samples were estimated qualitatively by electrophoresis on 0.8% agarose gels stained with ethidium bromide, and the bands were viewed in a UV transilluminator. The quantitative estimation of DNA was performed using a Nanodrop Spectrophotometer and taking the ratio of absorbance at 260/280 nm.

The DNA samples were then genotyped for 30 SNPs of the 9p21 region ([Table 1](#tbl1){ref-type="table"}). The 9p21 SNPs were chosen based on 2 criteria: (A) extensive literature survey and (B) minor allele frequency (MAF) taken from the dbSNP site of the National Center for Biotechnology Information. We have chosen SNPs having MAF \>0.15. The SNP genotyping was performed by the MassARRAY^®^ technology (Sequenom platform) using the AGENA protocol.Table 1SNPs studied in the 9p21.3 region.Table 1S. No.SNP IDChromosomal position[a](#tbl1fna){ref-type="table-fn"}Gene viewFunctional consequenceMinor allele and global frequency1rs1004638 (T/A)22115590CDKN2B-AS1Intron variantA- 0.312rs10116277 (T/G)22081398CDKN2B-AS1Intron variantG- 0.3233rs1011970 (G/T)22062135CDKN2B-AS1Intron variantT- 0.2474rs1063192 (A/G)22003368CDKN2B-AS1Intron variant, UTR variant 3′G- 0.2055rs10757272 (C/T)22088261CDKN2B-AS1Intron variantT- 0.456rs10757274 (A/G)22096056CDKN2B-AS1Intron variantG- 0.4047rs10757278 (A/G)22124478Near CDKN2B-AS1Intron variantG- 0.4088rs10757283 (C/T)22134173Near CDKN2B-AS1Intron variantT- 0.4979rs10811661 (T/C)22134095Near CDKN2B-AS1Intron variantC- 0.17610rs1333040 (T/C)22083405CDKN2B-AS1Intron variantC- 0.38311rs1333042 (G/A)22103814CDKN2B-AS1Intron variantA- 0.32112rs1333045 (T/C)22119196CDKN2B-AS1Intron variantC- 0.49813rs1333048 (A/C)22125348Near CDKN2B-AS1Intron variantC- 0.44214rs1333049 (G/C)22125504Near CDKN2B-AS1Intron variantC- 0.41815rs16905599 (G/A)22069145CDKN2B-AS1Intron variantA- 0.19016rs2383206 (A/G)22115027CDKN2B-AS1Intron variantG- 0.48717rs2383207 (G/A)22115960CDKN2B-AS1Intron variantA- 0.31018rs2383208 (A/G)22132077Near CDKN2B-AS1Intron variantG- 0.21019rs2811712 (A/G)21998036CDKN2B-AS1Intron variantG- 0.16020rs2891169 (A/G)22131826Near CDKN2B-AS1Intron variantG- 0.49321rs3731239 (A/G)21974219CDKN2AIntron variantG- 0.17522rs4977574 (A/G)22098575CDKN2B-AS1Intron variantG- 0.39523rs4977756 (A/G)22068653CDKN2B-AS1Intron variantG- 0.28824rs564398 (T/C)22029548CDKN2B-AS1Intron variant, nc transcript variantC- 0.18425rs615552 (T/C)22026078CDKN2B-AS1Intron variantC- 0.19526rs6475606 (T/C)22081851CDKN2B-AS1Intron variantC-0.32227rs7023329 (A/G)21816529MTAPIntron variantG- 0.44928rs7865618 (A/G)22031006CDKN2B-AS1Intron variantG- 0.18829rs944797 (T/C)22115287CDKN2B-AS1Intron variantC- 0.48730rs9632884 (C/G)22072302CDKN2B-AS1Intron variantG- 0.304[^1][^2]

IFNA21 is a proinflammatory cytokine, and elevated serum IFNA21 levels have been associated with the 9p21 risk locus.[@bib37] To examine the association between 9p21 SNPs and the expression of IFNA21 gene, the serum circulating levels of the cytokine were estimated using sandwich enzyme linked immuno sorbent assay (ELISA) (Wuhan Fine Biotech kit method) in a random subset of the entire sample that included 184 controls and 167 CAD cases. The IFNA21 gene is located 946,000 base pairs downstream of "core CAD" region in the IFNA gene cluster.

2.3. Statistical analyses {#sec2.3}
-------------------------

Demographic data were analyzed using SPSS software (Statistical Package for Social Sciences, version 21). The SNP data were analyzed using SPSS (version 21), SNPStats[@bib38] (available online), Haploview[@bib39] (available online), and multifactor dimensionality reduction (MDR)[@bib40] software (version 3.2). Two-tailed P values were considered to assess the significance of association in Chi-square tests used in all the statistical analyses. The power of the study was estimated by using online available software M GAS (Genetic Association Study) Power Calculator (version 3) and found to be 0.966.

3. Results and discussion {#sec3}
=========================

Demographic data analysis revealed a higher frequency of conventional risk factors such as diabetes, hypertension, hyperlipidemia, smoking, alcohol, nonvegetarian diet, low fruit intake, lack of physical exercise, and family history (affected first-degree relative) in CAD cases as compared to controls ([Table 2](#tbl2){ref-type="table"}). We compared demographic and clinical characteristics between premature CAD cases (age at presentation \<55 years in men and \<65 years in women) and nonpremature CAD cases ([Table 3](#tbl3){ref-type="table"}). Analysis revealed that frequency of females and individuals with diabetes, hypertension, and nonvegetarian diet is significantly higher in premature cases as compared to nonpremature cases. Premature cases did not score well with respect to lifestyle habits, except for regular fruit intake. Our results suggest that lifestyle habits and an increased genetic predisposition may play an important role in the etiopathology of premature CAD.Table 2Epidemiological characteristics of the study population.Table 2Demographic/clinical parameterControlsCases*P* valueAge in years (mean ± SD)51.8 ± 9.855.9 ± 10.71 × 10^−6^Percentage of males/females36.6/63.481.2/18.8\<1 × 10^−7^Height in cms (mean ± SD)157.61 ± 10163.49 ± 8.13 × 10^−3^Weight in Kg (mean ± SD)67.5 ± 11.667.8 ± 11.70.603BMI (mean ± SD)26.1 ± 4.925.4 ± 3.80.044Systolic BP (mean ± SD)121.4 ± 6.7125.7 ± 18.18 × 10^−4^Diastolic BP (mean ± SD)80.8 ± 5.976.6 ± 10.71 × 10^−7^Percentage of diabetics/normal15.8/84.250.5/49.5\<1 × 10^−7^Duration of diabetes in years (mean ± SD)0.431 ± 1.131.50 ± 1.80\<1 × 10^−7^Percentage of hypertensives/normal24.6/75.458.7/41.3\<1 × 10^−7^Duration of hypertension in years (mean ± SD)0.76 ± 1.551.74 ± 1.82\<1 × 10^−6^Percentage having affected first-degree relative/no affected first-degree relative30/7039.4/60.60.015Percentage of cigarette smokers (ever)/nonsmokers4.7/95.343.6/56.4\<1 × 10^−7^No. of cigarettes per day (mean ± SD)0.13 ± 0.924.21 ± 7.30\<1 × 10^−7^Percentage of alcoholics (ever)/nonalcoholics9.5/90.539.5/60.5\<1 × 10^−7^Number of pegs of alcohol (mean ± SD)1.85 ± 1.101.01 ± 1.40\<1 × 10^−7^Number of tea/coffee cups per day (mean ± SD)2.37 ± 1.122.69 ± 1.860.021Percentage of individuals with vegetarian diet/mixed diet51.9/48.117.9/82.1\<1 × 10^−7^Percentage of individuals with regular fruit intake/rare fruit intake75/2556.9/43.12 × 10^−6^Percentage of individuals with regular physical exercise/no physical exercise78.3/21.745.5/54.5\<1 × 10^−7^[^3]Table 3Comparison of epidemiological and clinical variables between nonpremature and premature cases.Table 3S. No.Variable% of Nonpremature cases (*n* = 109)% of Premature cases (*n* = 109)*P* value1.**Gender**Male86.775.2**0.030**Female13.324.82.**Diabetes**Yes58.441.9**0.015**No41.658.13.**Hypertension**Yes70.845.7**0.0002**No29.254.34.**Hyperlipidemia**Yes10.613.30.404No55.846.7No information33.640.05.**Alcohol**Yes36.342.90.321No63.757.16.**Smoking habit**Yes40.746.70.375No59.353.37.**Exercise**Yes49.6410.202No50.4598.**Food habit**Vegetarian23.911.4**0.016**Mixed76.188.69.**Fruits intake**Daily38.137.10.5921--2 times weekly5.36.73--4 times weekly10.616.2Occasionally/rarely46.040.010.**Family history**Yes37.641.60.597No62.458.4

3.1. SNP data analysis {#sec3.1}
----------------------

The genotypic and allele frequency distribution of the 30 SNPs among the controls and CAD and premature CAD cases revealed that the CC genotype of rs1333045 (T/C) showed more than 1.4-fold risk for CAD (*P* = 0.046 in the recessive model). We found more than 1.6-fold risk for premature CAD (*P* = 0.051 in the recessive model). Our study is the first to report an association of rs1333045 with CAD risk in an Asian Indian population.

The CC genotype of rs1333049 (G/C), a highly replicated SNP, showed a trend toward risk association with premature CAD in the study population (*P* = 0.061 in the recessive model).[@bib41], [@bib42]

Further, we found that the AA genotype of rs16905599 (G/A) is associated with more than 2.4-fold risk for CAD in the study population (*P* = 0.025 in the codominant model and *P* = 0.0069 in the recessive model). The AA genotype of rs16905599 showed about threefold risk for premature CAD (*P* = 0.018 in the codominant model and *P* = 0.0081 in the recessive model). *This is a first ever report of an association of rs16905599 (AA) with CAD indicating its potential as a useful genetic marker for CAD in the local population*.

In addition, rs2383206 (A/G) showed robust association with CAD in the study population where the GG genotype of rs2383206 conferred about twofold risk for CAD (*P* = 0.0004 in the codominant model and *P* = 0.0001 in the recessive model)[@bib42], [@bib43] and 2.4-fold risk for Premature CAD (*P* = 0.0002 in Recessive model).

An interesting case of under dominance (risk associated with only heterozygote) was found in case of rs2383208 (A/G) where the AG genotype showed about 1.7-fold risk for premature CAD (*P* = 0.021 in the codominant model and *P* = 0.034 in the overdominant model). We found a similar trend in all CAD cases (*P* = 0.051 in the overdominant model). The GG genotype of rs4977574 (A/G) was also associated with more than 1.7-fold risk for premature CAD (*P* = 0.025 in the recessive model).[@bib42]

Thus, the present study identified SNPs rs1333049 (CC) and rs4977574 (GG)[@bib41], [@bib42] to be associated exclusively with premature CAD in the local population, suggesting that these have the potential to be used as markers to identify asymptomatic individuals at a higher risk of premature CAD. However, these results require further validation in larger cohorts.

We performed association analysis using SNPStats by adjustment for the following covariates: age, gender, diabetes, hypertension, hyperlipidemia, smoking, alcohol, and family history. The SNPs that showed significant risk association despite adjustment for the covariates were rs2383206, rs16905599, and rs2383208. Of the three SNPs, rs2383206 consistently showed the strongest CAD risk association with odds ratio greater than 2 in our study population. Hence, rs2383206, rs16905599, and rs2383208 have the potential to be used as 9p21 markers along with markers at other loci to generate a more reliable genetic risk score (GRS) for CAD in the local population.

We used the Bonferroni correction to reduce the probability of false-positive results (type I errors) and found that only SNP rs2383206 showed significant risk association with CAD (*P* \< 0.0016) after doing multiple testing corrections for the 30 9p21 SNPs studied.

Upon gender stratification of the SNP genotyping data, we found that the TT and TC genotypes of SNP rs10757272 (C/T) showed an eightfold to ninefold significant risk association (*P* = 0.0032 in the dominant model and *P* = 0.012 in the codominant model) with CAD specifically among females.

The GG genotype of SNP rs7865618 (A/G) showed more than 2.5-fold risk association (*P* = 0.037 in the recessive model) with CAD specifically among males.

3.2. Multivariate logistic regression, MDR, and Haploview analysis {#sec3.2}
------------------------------------------------------------------

We performed multivariate logistic regression analysis of 30 9p21 SNPs with 12 demographic/clinical variables ([Table 4](#tbl4){ref-type="table"}). Our analysis revealed association of several 9p21 SNPs with demographic and clinical variables such as age, diabetes, hyperlipidemia, Rh blood groups, ABO blood groups, food habit, and fruit intake.Table 4Association of SNPs with demographic and clinical parameters using multivariate logistic regression analysis.Table 4S. No.SNP ID/variable[a](#tbl4fna){ref-type="table-fn"}Wild-type genotype/reference valueRisk genotype/OR with 95% CI*P* valueHeterozygous genotype/OR with 95% CI*P* value1.rs1004638TT(1)AAATAFruits intake0.676 (0.469--0.974)**0.036**0.767 (0.576--1.022)0.0702.rs10116277TT(1)GGGTARh blood groups3.394 (0.917--12.566)0.0673.137 (1.044--9.429)**0.042**BFood habit0.329 (0.097--1.115)0.074CHypertension1.930 (0.910--4.096)0.0873.rs1011970GG(1)TTTGAAlcohol consumption0.294 (0.070--1.235)0.095BExercise0.555 (0.278--1.110)0.0964.rs1063192AA(1)GGGAAAge0.205 (0.040--1.053)0.058BHyperlipidemia0.638 (0.376--1.084)0.0965.rs10757272CC(1)TTCTAAge2.703 (0.918--7.958)0.0716.rs10757274AA(1)GGAGARh blood groups0.216 (0.059--0.785)**0.020**BFruits intake1.388 (0.998--1.932)0.051CFood habit2.656 (0.971--7.266)0.0577.rs10757578AA(1)GGAGARh blood groups0.354 (0.108--1.157)0.086BHyperlipidemia0.565 (0.307--1.040)0.067CFood habit2.801 (0.898--8.736)0.0768.rs10811661TT(1)CCCTAFood habit2.739 (0.920--8.154)0.0709.rs1333040TT(1)CCCTAAge2.292 (1.034--5.079)**0.041**BRh blood group2.665 (0.998--7.117)**0.050**CFood habit0.282 (0.082--0.975)**0.045**10.rs1333042GG(1)AAAGAAge2.461 (1.093--5.544)**0.030**BRh blood group3.045 (1.094--8.478)**0.033**CFruits intake0.720 (0.488--1.060)0.09611.rs1333045TT(1)CCCTARh blood group0.287 (0.085--0.972)**0.045**12.rs1333048AA(1)CCCAARh blood groups0.263 (0.071--0.969)**0.045**BFood habit3.385 (1.110--10.324)**0.032**3.905 (1.462--10.430)**0.007**13.rs1333049GG(1)CCCGAFood habit3.206 (1.029--9.991)**0.045**3.222 (1.232--8.424)**0.017**BFruits intake1.316 (0.951--1.821)0.09714.rs16905599GG(1)AAAGAAlcohol consumption0.273 (0.065--1.155)0.078BRh blood group4.052 (1.500--10.948)**0.006**CHyperlipidemia1.678 (0.939--2.999)0.08015.rs2383206AA(1)GGAGAFruits intake1.365 (0.986--1.891)0.0611.424 (1.023--1.981)**0.036**16.rs2383207GG(1)AAAGAAge2.430 (1.073--5.501)**0.033**BRh blood group2.887 (1.041--8.011)**0.042**17.rs2383208AA(1)GGGAAAge7.737E+136 (7.737E+136 to 7.737E+136)**0.000**BFood habit2.349 (0.878--6.282)0.089CFruit intake1.285 (0.994--1.660)0.05518.rs2811712AA(1)GGAGAAge5455280.330 (5455280.330--5455280.330)**0.000**19.rs2891169AA(1)GGAGADiabetes0.241 (0.081--0.719)**0.011**0.246 (0.092--0.656)**0.005**BSmoking0.328 (0.101--1.063)0.063CHyperlipidemia0.523 (0.258--1.060)0.07220.rs4977574AA(1)GGGAARh blood groups0.236 (0.065--0.855)**0.028**BFood habit2.509 (0.832--7.565)0.1022.675 (1.025--6.981)**0.044**CFruit intake1.354 (0.980--1.871)0.06621.rs4977756AA(1)GGGAAAge2.089 (0.907--4.810)0.083BDuration of CAD0.432 (0.180--1.037)0.060CHyperlipidemia0.603 (0.351--1.038)0.06822.rs615552TT(1)CCCTAAge2.319 (1.024--5.249)**0.044**BExercise0.542 (0.260--1.129)0.102CDuration of CAD0.331 (0.134--0.816)**0.016**DHyperlipidemia0.521 (0.300--0.905)**0.021**23.rs6475606TT(1)CCCTAAge2.684 (1.150--6.265)**0.022**BDuration of CAD0.364 (0.148--0.892)**0.027**CHypertension1.992 (0.934--4.252)0.075DRh blood group3.003 (1.046--8.623)**0.041**24.rs7023329AA(1)GGGAAABO blood groups1.383 (1.039--1.840)**0.026**BHyperlipidemia6.096 (1.595--23.302)**0.008**25.rs944797TT(1)CCCTAABO blood groups0.711 (0.487--1.039)0.078BRh blood groups0.369 (0.112--1.210)0.100CFood habit3.066 (0.931--10.100)0.065DFruit intake1.562 (1.123--2.171)**0.008**1.443 (1.038--2.005)**0.029**26.rs9632884CC(1)GGGCAAge2.584 (1.149--5.815)**0.022**BABO blood groups0.766 (0.569--1.029)0.077CFruit intake0.768 (0.594--0.992)**0.043**[^4][^5]

Further, we examined SNP--SNP interactions and SNP--demographic/clinical variable interactions using MDR analysis for ten 9p21 SNPs showing good risk association trends with CAD: rs1011970, rs10757272, rs10757274, rs1333045, rs1333049, rs16905599, rs2383206, rs2383208, rs4977574, and rs7865618.

MDR risk prediction model analysis revealed that rs2383206 is the best one-locus model, and rs16905599 with rs2383206 is the best two-locus model in the study population.

With respect to SNP--SNP interactions, MDR analysis revealed a mild interaction between rs10757272 and rs2383208.

SNPs rs1333045, rs16905599, rs7865618, rs10757274, and rs2383206 showed no interaction among themselves. Therefore, these SNPs (showing significant risk association with CAD in our study population) appear to be operating independent of each other ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1MDR analysis: SNP--SNP interactions. MDR, multifactor dimensionality reduction; SNP, single-nucleotide polymorphism.Fig. 1

With respect to SNP--demographic/clinical variable interactions, a moderate interaction was observed among the variables body mass index, age, and fruit intake, whereas a mild interaction was observed among hypertension, diabetes, and serum IFNA21 levels. Similarly, there is a mild interaction between exercise and food habit. The variables alcohol, smoking, gender, and hyperlipidemia are found to be operating independently ([Fig. 2](#fig2){ref-type="fig"}). This corroborates the observation that the 9p21 locus confers CAD risk independent of classic risk factors.[@bib4], [@bib7]Fig. 2MDR analysis: SNP--demographic/clinical variable interactions. MDR, multifactor dimensionality reduction; SNP, single-nucleotide polymorphism; BMI, body mass index.Fig. 2

Linkage disequilibrium (LD) analysis was performed using Haploview software to generate LD plots for controls and cases. Our analysis has revealed six blocks (blocks 1, 2, 3, 4, 5, and 6) of linked SNP variants in controls and three blocks (blocks 1, 2, and 3) in cases ([Fig. 3](#fig3){ref-type="fig"}). Similarly, six blocks (blocks 1, 2, 3, 4, 5, and 6) of linked SNP variants were observed for the entire sample ([Fig. 4](#fig4){ref-type="fig"}).Fig. 3LD plot for controls and cases. LD, linkage disequilibrium.Fig. 3Fig. 4LD plot for all subjects. LD, linkage disequilibrium.Fig. 4

One limitation of our study is the limited size of CAD cases. Hence, the results need to be validated in larger CAD cohorts. Our study subjects have been taken from the twin cities of Hyderabad and Secunderabad, irrespective of the geographical region, language, caste group, and community they hail from. Most CAD cases have been taken from KIMS hospital, Secunderabad, which is centrally located and receives patients from different parts of the state and country. Despite these measures, there may be a possibility of a hidden population substructure that has not been considered in this study.

4. Conclusions {#sec4}
==============

Premature CAD cases showed a significantly higher frequency of females, diabetics, hypertensives, and individuals with nonvegetarian food habit as compared to nonpremature cases. SNPs rs1333045 (CC), rs16905599 (AA), rs2383206 (GG), rs2383208 (AG), and rs4977574 (GG) showed significant risk association with premature CAD in our study population. We found rs1333049 (CC) and rs4977574 (GG) to be associated exclusively with premature CAD, suggesting their potential as genetic markers to predict premature CAD in the local population. Of all the 9p21 SNPs that showed significant CAD risk association, rs2383206 emerged as the strongest genetic risk factor followed by rs16905599 and rs2383208. SNP rs10757272 (TT and TC) has shown a robust female-specific risk association, and SNP rs7865618 (GG) has shown significant male-specific risk association with CAD in our study population.

To conclude, results of the present study suggest that SNPs at the 9p21 risk locus may be used to generate a reliable GRS along with markers at other loci. This could be used for presymptomatic diagnosis in high-risk families such that suitable therapeutic measures could be advised to prevent the serious outcomes of acute coronary syndromes.**Key messagesWhat is already known about this subject?**•The 9p21 risk locus is independent of most traditional risk factors of CAD such as high lipids, hypertension, obesity, and diabetes. The association of SNPs at this locus with CAD has been replicated in many ethnicities. 9p21 is also known to be a predictor of severity of CAD based on the number of vessels involved. The 9p21 risk locus has shown about twofold greater risk in individuals who develop premature CAD (\<55 years in men and \<65 years in women). This locus mediates its risk at the vessel wall leading to the onset of atherosclerosis in coronary arteries, thereby resulting in CAD. The 9p21 locus may have clinical utility as an early marker for CAD risk.**What does this study add?**•Our study suggests that female gender may be at higher risk of premature CAD. Lifestyle factors and genetic predisposition may have a major role to play in the etiopathology of premature CAD.•Our study has reported a first ever risk association of SNPs rs1333045 (CC) and rs16905599 (AA) with CAD in an Asian Indian population.•SNPs rs1333049 (CC) and rs4977574 (GG) have potential as genetic markers to identify individuals at a higher risk of premature CAD.•Some demographic and clinical variables have shown significant association with 9p21 SNP genotypes.•SNP rs2383206 is the strongest genetic risk factor for CAD followed by rs16905599 and rs2383208 in the study population.•SNP rs10757274 (TT and TC) has shown a strong female-specific risk association and rs7865618 (GG) has shown a significant male-specific risk association with CAD in the study population.**How might this impact clinical practice?**This study aimed to identify and understand the unique pattern of risk factors, especially those at the chromosome 9p21.3 locus in our local population. This may contribute to presymptomatic diagnosis in high-risk families and development of preventive/therapeutic strategies most suited to our population in the near future. The 9p21.3 locus also holds good promise for pharmacogenetics research and clinical applications, so that medical treatment could be personalized to suit individuals based on their complex genetic and environmental backgrounds. However, these results require further validation in larger cohorts.
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[^1]: SNP, single-nucleotide polymorphism.

[^2]: Genome build is GRCh38.p12 (taken from dbSNP site).

[^3]: SD, standard deviation; BMI, body mass index; BP, blood pressure.

[^4]: SNP, single-nucleotide polymorphism; CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.

[^5]: The variables included for multivariate logistic regression analysis are age at onset, duration of CAD, diabetes, hypertension, hyperlipidemia, ABO blood groups, Rh blood groups, alcohol habit, smoking habit, physical exercise, food habit, and fruit intake. Only variables for which there is an association or trend towards an association have been shown in the table for each SNP.
